Navigation Links
NeurogesX to Present at 10th Annual JMP Securities Research Conference
Date:5/5/2011

SAN MATEO, Calif., May 5, 2011 /PRNewswire/ -- NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 10th Annual JMP Securities Research Conference, to be held May 9-11, 2011, in San Francisco, CA. Event:

10th Annual JMP Securities Research Conference Date:

Monday, May 9, 2011Time:

1:30 PM Pacific TimePlace:

Terrace Room, The Ritz-Carlton, San Francisco, CAThe presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcast will be archived for 90 days.

About NeurogesX, Inc.NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza®, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza® is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza® is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza® for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor StatementThis press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: the potential submission to the U.S. Food and Drug Administration of a supplemental new drug application for label expansion of Qutenza.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the commercialization of Qutenza, including with respect to manufacture and supply of Qutenza; unexpected adverse side effects of Qutenza; physician or patient reluctance to use Qutenza, despite the Company's efforts and strategies to commercialize Qutenza; and difficulties or delays in the further development of Qutenza and efforts towards label expansion; and potential competitors and competitive products. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310

The Ruth GroupStephanie Carrington (investors)

(646) 536-7017

scarrington@theruthgroup.comJason Rando (media)

(646) 536-7025

jrando@theruthgroup.com
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeurogesX Reports First Quarter 2011 Results
2. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
3. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
4. NeurogesX to Provide Qutenza® Launch Update
5. NeurogesX to Present at Two February Investor Conferences
6. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
7. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
8. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
9. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
10. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
11. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... India , January 24, 2017 ... titled, "Cold Chain Logistics Market by Application Type (Fruits ... Meat, Fish & Sea Food, Drugs & Pharmaceuticals, and ... projects that the global cold chain logistics market is ... a CAGR of 16% (2016 to 2022). ...
(Date:1/24/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and ... finalists in the Regeneron Science Talent Search, the nation,s ... high school seniors. Finalists were selected based on the ... The finalists will now go to ... undergo a rigorous judging process to determine the top ...
(Date:1/24/2017)... 24, 2017 Research and Markets has announced ... Trends - Product, Material - Forecast to 2025" report to ... ... a CAGR of around 5.4% over the next decade to reach ... trends that the market is witnessing include 3D medical printing is ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... and eliminate cyber threats in real-time, today announced a strategic partnership with ... customers to monitor, respond and protect their critical information assets and infrastructure, in ...
(Date:1/24/2017)... ... 24, 2017 , ... His message has been heard by more than 100,000 ... Distracted Driving , Joel Feldman, has reached his biggest national audience yet: the three ... the top newspapers in circulation in the country, and he hopes it will help ...
(Date:1/24/2017)... ... ... Saturday, January 28, the BCFA presents more than 20 local performances including Chinese music, ... Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide a taste ... games, crafts & more. Festivities begin at 11:00 am and end at 2:30 pm. ...
(Date:1/24/2017)... ... January 24, 2017 , ... Inspiration, Community ... Well-meaning studies such as the Fordham Institute’s High Stakes for High Achievers ... such as including gifted or high-achieving students as a subgroup and reporting their ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January ... Sharon Kleyne, the nation’s foremost water advocate and host of the nationally syndicated ... on Voice America, once again welcomed one of her favorite guests and colleagues, ...
Breaking Medicine News(10 mins):